AstraZeneca ENHERTU Statistically Significant Overall Survival, Reducing Risk of Death 36% V. Roche Kadcyla

 AstraZeneca and Daiichi Sankyo’s ENHERTU also improved progression-free survival by 22 months vs. T-DM1 in patients previously treated with HER2-directed therapy in the DESTINY-Breast03 Phase III trial

ENHERTU showed significant progression-free and overall survival improvements vs. chemotherapy in later-line HER2-positive setting in the DESTINY-Breast02 Phase III trial

https://finance.yahoo.com/news/enhertu-fam-trastuzumab-deruxtecan-nxki-133000076.html